| Literature DB >> 20732592 |
Abstract
Mechanical damage to the spinal cord initiates a secondary injury cascade that results in ischemia, disturbances in ion concentrations, excitotoxicity, production of reactive oxygen species, inflammation, and apoptosis. Over weeks to months a glial scar forms, and scarring can result in the development of syringomyelia. In the early phase of the disease, treatment should focus on maintaining systemic blood pressure and oxygenation, decompression of the spinal cord, and stabilization, if indicated. There are currently no proven neuroprotective drug therapies for limiting secondary damage, but blinded clinical trials are underway. Transplantation with olfactory ensheathing cells and mesenchymal stem cells show promise, as do potassium channel antagonists. Canine clinical trials of these therapies are ongoing. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20732592 DOI: 10.1016/j.cvsm.2010.05.007
Source DB: PubMed Journal: Vet Clin North Am Small Anim Pract ISSN: 0195-5616 Impact factor: 2.093